Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1439-7609
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study ; day:3 ; month:5 ; year:2013 ; pages:1-9
Modern rheumatology ; (3.5.2013), 1-9
- Creator
-
Nishimoto, Norihiro
Amano, Koichi
Hirabayashi, Yasuhiko
Horiuchi, Takahiko
Ishii, Tomonori
Iwahashi, Mitsuhiro
Iwamoto, Masahiro
Kohsaka, Hitoshi
Kondo, Masakazu
Matsubara, Tsukasa
Mimura, Toshihide
Miyahara, Hisaaki
Ohta, Shuji
Saeki, Yukihiko
Saito, Kazuyoshi
Sano, Hajime
Takasugi, Kiyoshi
Takeuchi, Tsutomu
Tohma, Shigeto
Tsuru, Tomomi
Ueki, Yukitaka
Yamana, Jiro
Hashimoto, Jun
Matsutani, Takaji
Murakami, Miho
Takagi, Nobuhiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10165-013-0894-z
- URN
-
urn:nbn:de:101:1-2019062920200158226157
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nishimoto, Norihiro
- Amano, Koichi
- Hirabayashi, Yasuhiko
- Horiuchi, Takahiko
- Ishii, Tomonori
- Iwahashi, Mitsuhiro
- Iwamoto, Masahiro
- Kohsaka, Hitoshi
- Kondo, Masakazu
- Matsubara, Tsukasa
- Mimura, Toshihide
- Miyahara, Hisaaki
- Ohta, Shuji
- Saeki, Yukihiko
- Saito, Kazuyoshi
- Sano, Hajime
- Takasugi, Kiyoshi
- Takeuchi, Tsutomu
- Tohma, Shigeto
- Tsuru, Tomomi
- Ueki, Yukitaka
- Yamana, Jiro
- Hashimoto, Jun
- Matsutani, Takaji
- Murakami, Miho
- Takagi, Nobuhiro
- SpringerLink (Online service)
Other Objects (12)
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
Tocilizumab-Induced Erythema Annulare Centrifugum
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
Tocilizumab-Induced Erythema Annulare Centrifugum
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
Tocilizumab-Induced Erythema Annulare Centrifugum
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report